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Abstract
Background: The adaptor protein p130Cas (Cas) has been shown to be involved in different
cellular processes including cell adhesion, migration and transformation. This protein has a
substrate domain with up to 15 tyrosines that are potential kinase substrates, able to serve as
docking sites for proteins with SH2 or PTB domains. Cas interacts with focal adhesion plaques and
is phosphorylated by the tyrosine kinases FAK and Src. A number of effector molecules have been
shown to interact with Cas and play a role in its function, including c-crk and v-crk, two adaptor
proteins involved in intracellular signaling. Cas function is dependent on tyrosine phosphorylation
of its substrate domain, suggesting that tyrosine phosphorylation of Cas in part regulates its control
of adhesion and migration. To determine whether the substrate domain alone when tyrosine
phosphorylated could signal, we have constructed a chimeric Cas molecule that is phosphorylated
independently of upstream signals.
Results: We found that a tyrosine phosphorylated Cas substrate domain acts as a dominant
negative mutant by blocking Cas-mediated signaling events, including JNK activation by the
oncogene v-crk in transient and stable lines and v-crk transformation. This block was the result of
competition for binding partners as the chimera competed for binding to endogenous c-crk and
exogenously expressed v-crk.
Conclusion: Our approach suggests a novel method to study adaptor proteins that require
phosphorylation, and indicates that mere tyrosine phosphorylation of the substrate domain of Cas
is not sufficient for its function.
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Background
Metastasis of tumor cells is critically dependent on the
ability of cancer cells to adhere and migrate. The cell sur-
face expressed integrins can control this process by physi-
cally interacting with the extracellular matrix proteins and
other cell surface proteins on endothelial cells lining the
blood vessel wall [1]. These integrins signal adhesion and
migration by communicating with several tyrosine kinas-
es inside the cell, including the Focal Adhesion Kinase
(FAK) and Src family kinases [1,2]. Src kinases control the
activation of FAK, as well as the tyrosine phosphorylation
of critical substrates that regulate adhesion and migration
[3]. Indeed, colon cancer cells with high metastatic poten-
tial have elevated levels of Src activity or activating muta-
tions in the Src gene [4,5]. One Src substrate that is
involved in regulating an important signaling node in this
process is the adaptor protein p130cas (Cas) [6–10]. Cas
appears to play a central role in the transformation proc-
ess by several oncogenes including ras, ornithine decar-
boxylase (ODC), v-Src, v-crk, and Bcr-Abl, as these tumors
all have elevated levels of tyrosine phosphorylated Cas
[6,11–13]. Cells from mice that lack Cas have much re-
duced migration and are resistant to transformation by v-
Src, while expression of Cas anti-sense RNA in cells trans-
formed with ras, v-Src or ODC result in reversion of the
transformed phenotype [11,14,15]. Furthermore, in-
creased expression of Cas can rescue cell migration and
adhesion in cells expressing the tumor suppressor PTEN,
and can enhance cell migration and adhesion in normal
cells, with a major role being played by the substrate do-
main [16,17].
Cas is a protein which migrates with an apparent mass of
approximately 130 kDa, with a N-terminal SH3 domain,
a central substrate domain (SD) with up to 15 tyrosines
which can be phosphorylated, a C-terminal region with a
proline-rich region, and two tyrosine phosphorylation
sites capable of binding Src kinases (Src binding domain
(SBD)) [6,18]. The latter SBD domain regulates the ability
of Src to activate the serum response element, as well as in
the phosphorylation of the SD of Cas by Src [18–20]. The
substrate domain controls adhesion and migration and
the majority of the tyrosines within this domain are of the
sequence YQXP (5) or YDXP (10), which when phospho-
rylated, bind to the adaptors c-crk, nck and AND-34
[16,21–23]. The importance of these molecules in Cas
function is unclear, however c-crk seems to be critical in
the regulation of adhesion and migration mediated by
Cas. In addition, the SH3 domain of Cas mediates an in-
teraction with FAK, C3G, CMS, and the zinc finger con-
taining protein CIZ, while nephrocystin interacts with Cas
via its SH3 domain and proline rich sequences in Cas [24–
30]. The SH3 domain of Cas can also interact with the ty-
rosine phosphatase PTP1B, and expression of PTP1B in
transformed cells reverts the phenotype, in part by de-
phosphorylating Cas [31,32].
Tyrosine phosphorylation of Cas is regulated by adhesion,
such that adherent and migrating cells have high levels of
tyrosine phosphorylated Cas, whereas cells in suspension
have reduced levels of Cas phosphorylation [10,33]. In
addition, as mentioned above, transformed cells that are
able to grow in an anchorage independent manner show
increased tyrosine phosphorylation of Cas [10,33]. These
data suggest that tyrosine phosphorylation of Cas in part
regulates a switch from adhesion dependent growth to ad-
hesion independent growth. Whether mere tyrosine phos-
phorylation or localization of Cas is more important for
its regulation of adhesion and migration is unclear. Tyro-
sine phosphorylation of adaptor molecules such as Cas is
dependent on upstream signals that lead to the phospho-
rylation of the adaptor, and with multiple pathways lead-
ing from these upstream signals it is difficult to tease out
the events resulting from the phosphorylated adaptor it-
self. We have tried to address this problem by constructing
a chimeric Cas molecule (Src*/Cas(SD)) that is phospho-
rylated independently of upstream signals by fusing the
SD of Cas to a Src kinase domain that had been attenuated
by mutating the activation tyrosine (Y416) to phenyla-
lanine. Such a mutant is inactive against exogenous sub-
strates [34–36]. We found that this Src*/Cas(SD)
molecule is constitutively tyrosine phosphorylated when
expressed either transiently or stably in cells, and acts as a
dominant negative mutant, attenuating v-crk mediated
transformation when expressed in cells transformed by
this oncogene. We also observed a reduction in basal JNK
activity in normal cells expressing this chimera and in v-
crk mediated activation of JNK in cell expressing both v-
crk and the chimera. By contrast, tyrosine phosphoryla-
tion of endogenous Cas and FAK was unaffected by the
Cas chimera, indicating that these processes lie upstream
of the tyrosine phosphorylated Cas SD. Finally, we show
that this chimera can act as a decoy to selectively disrupt
signaling events downstream of the tyrosine phosphor-
ylated SD of endogenous Cas, acting as a dominant nega-
tive mutant. We suggest that this approach and modified
versions of this approach can be a general method to de-
termine the role of tyrosine phosphorylated domains
without regard to upstream signals.
Results
Creation of a dominantly tyrosine phosphorylated Cas 
substrate domain
The adaptor protein Cas has a N-terminal SH3 domain, a
large number of tyrosines that serve as potential kinase
substrates within its substrate domain and a C-terminal
Src binding domain (Fig. 1). Understanding the function
of this substrate domain and the tyrosines within it could
lead to a better understanding of the signaling pathwaysBMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/18
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regulated by this protein. Previously, investigators have
created dominant negative versions of this protein lacking
its substrate domain and shown that it is required for cell
adhesion and migration. However, these studies depend
on upstream signals and so it is not clear which signals are
directly emanating from the substrate domain itself, as
this domain requires the activation of upstream kinases
for its phosphorylation and function. We have tried to ad-
dress this problem by attempting to create a dominant ac-
tive substrate domain of Cas, i.e. a Cas substrate domain
that is constitutively tyrosine phosphorylated and able to
send signals independently of upstream signals. We did
this by fusing the SD of Cas to a Src kinase domain that
had been attenuated by mutating the activation tyrosine
(Y416) to phenylalanine (Src*/Cas(SD), Fig. 2). This Src
mutant is inactive against exogenous substrates [34–36].
We also generated fusions of the Cas SD with a Src kinase
inactive mutant (K295M) that has no enzymatic activity
(SrcKM/Cas(SD)), fusions of either the attenuated kinase
domain or kinase inactive domain to the 5' or 3' regions
of the Cas SD (Src*/Cas(5'SD), Src*/Cas(3'SD), SrcKM/
Cas(5'SD), SrcKM/Cas(3'SD)), as well as the attenuated
Src kinase (Src*) alone without the attached Cas SD (Fig.
2). Transient expression of the Src*/Cas(SD) in Cos-7 cells
followed by analysis of total cell lysates using anti-phos-
photyrosine antibodies demonstrated that while the at-
tenuated Src kinase domain alone did not increase total
cellular tyrosine phosphorylated proteins as expected, ex-
pression of the Src*/Cas(SD) fusion resulted in tyrosine
phosphorylation of a protein of the expected size of the
chimera, as well as other proteins (Fig. 3a, 3b). Expression
of the Cas(SD) or the SrcKM/Cas(SD), fusion did not re-
sult in any increase in total phosphotyrosine containing
proteins nor in the tyrosine phosphorylation of the Cas
SD (data not shown and see Fig. 4).
The C-terminus of the Cas SD is involved in the interaction 
with v-crk
Investigators have shown that v-crk interacts via its SH2
domain with the substrate domain of Cas [6]. Association
of v-crk with endogenous Cas is believed to protect the
phosphorylation status of this molecule due to protection
from phosphatases [12]. Expression of an unphosphor-
ylated Cas SD along with v-crk should therefore result in
stable tyrosine phosphorylation of the Cas SD if they in-
teract. The Cas SD has two sets of potential SH2 interact-
ing tyrosines, the N-terminal subdomain containing 4
YQXP motifs located between a.a. L157 to A324 and the C-
terminal subdomain containing, 9 YDXP motifs located
between a.a. S325 to R516. The v-crk SH2 domain interacts
with YXXP motifs upon phosphorylation, suggesting that
both of these regions may be able to interact with v-crk
[37]. Fusions of the kinase inactive Src kinase domain and
either the full Cas SD, the 5' region of the Cas SD
(Cas(5'SD), containing 4 YQXP motifs) or the 3' of the
Cas SD (Cas(3'SD), containing 9 YDXP motifs), are not
stably tyrosine phosphorylated when expressed alone in
cells (data not shown and see Fig. 4b). We therefore used
these fusions to determine which region of the Cas SD in-
teracts with v-crk. Initially, we expressed the SrcKM/
Cas(SD) (entire Cas SD) in Cos-7 cells alone, or along
with wild type (WT) v-crk, or v-crk SH2 or SH3 mutants
and assayed for tyrosine phosphorylation and association
by co-immunoprecipitation (Fig. 4a). Figure 4a demon-
strates that while the chimera was not stably tyrosine
phosphorylated when expressed alone, expression of the
SrcKM/Cas(SD) chimera along with either WT or an SH3
domain mutant of v-crk resulted in its stable tyrosine
phosphorylation and co-immunoprecipitation with v-crk
(Fig. 4a, lanes 2 & 4). However, co-expression of the
SrcKM/Cas(SD) chimera along with a SH2 mutant of v-crk
demonstrated that an intact v-crk SH2 domain is required
for association with the tyrosine phosphorylated SrcKM/
Cas(SD) (Fig. 4a, lane 3). These data suggest that the ki-
nase inactive fusion with the Cas SD is either transiently
tyrosine phosphorylated in cells and v-crk protects them
from being dephosphorylated by interacting with them
via its SH2 domain, or alternatively, that v-crk induces
their tyrosine phosphorylation.
We then used the 5' and 3' fusions of the Cas SD to deter-
mine which motif, YQXP or YDXP, interacts with the v-crk
SH2 domain. Expression of the SrcKM fused to the full
length Cas SD, 5' N-terminal YQXP motifs or 3' C-termi-
nal YDXP motifs alone demonstrated that these fusions
were not stably tyrosine phosphorylated in cells (Fig. 4b,
lanes 1–3), although they can be stably tyrosine phospho-
rylated when fused to the attenuated Src kinase domain
(data not shown and see Fig. 7a). By contrast, co-expres-
sion of these fusions along with v-crk results in stable ty-
rosine phosphorylation of the 3' C-terminal YDXP motifs
Figure 1
Structure of Cas. The SH3 domain, substrate domain and Src
interaction sites are indicated.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/18
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and the full length Cas SD (carrying both motifs), but not
the 5' N-terminal YQXP motifs (Fig. 4b, lanes 4–6). These
data indicate that the v-crk SH2 domain interacts with the
C-terminal YDXP motifs, and as suggested by Birge et al,
v-crk may be able to protect them from dephosphoryla-
tion and/or induces their phosphorylation [12]. They also
suggest that the YQXP motifs may be involved in binding
to other intracellular signaling molecules.
Suppression of v-crk mediated transformation by tyrosine 
phosphorylated Cas SD
As our tyrosine phosphorylated Cas SD chimera can inter-
act with v-crk, we decided to find out if the chimera would
affect cell growth and/or transformation in normal cells
and those transformed with v-crk. NIH3T3 cells or those
transformed with v-crk were stably transfected with the
Cas SD chimera (Fig. 5). Several independent clones were
obtained for each set of transfections suggesting that ex-
pression of the tyrosine phosphorylated Cas SD domain
did not negatively affect cell growth (data not shown).
Figure 5a demonstrates that stable expression of the Src*/
Cas(SD) chimera resulted in constitutive tyrosine phos-
phorylation of this protein in NIH3T3 cells. Analysis of
the effect of this chimera in non-transformed NIH3T3
cells indicates that these cells were not transformed and
had normal morphology, although they grew slightly
slower than vector-transfected cells (data not shown).
Analysis of the growth of either non-transformed or v-crk
transformed NIH3T3 cells in soft agar confirmed that ex-
pression of tyrosine phosphorylated Cas SD chimera did
Figure 2
Structure of attenuated Src kinase domain/Cas chimeras. The Src/Cas(SD) chimeras were constructed as described in the
materials and methods. Src* is the isolated attenuated Src kinase domain (Y416F). Src*/Cas(SD) is a fusion of the attenuated
Src kinase domain to a.a. L157 to R516 of the Cas substrate domain. Src*/Cas(5'SD) is a fusion of the attenuated Src kinase
domain to the 5' portion of the Cas substrate domain (a.a. L157 to A324). Src*/Cas(3'SD) is a fusion of the attenuated Src kinase
domain to the 3' portion of the Cas substrate domain (a.a. S325 to R516). SrcKM is the isolated inactive kinase domain (K295M).
SrcKM/Cas(5'SD) is a fusion of the inactive Src kinase domain to the 5' portion of the Cas substrate domain (a.a. L157 to R516).
SrcKM/Cas(3'SD) is a fusion of the inactive Src kinase domain to the 3' portion of the Cas substrate domain (a. a. S325 to R516).BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/18
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Figure 3
The Src*/Cas(SD) chimera is highly tyrosine phosphorylated when expressed in cells and associates with tyrosine phosphor-
ylated proteins. a) Cos-7 cells were transfected with vector alone (lane 1), plasmid coding for the isolated attenuated Src
kinase domain (lane 2) or the Src*/Cas(SD) chimera (lane 3). Cell lysates were probed with antibodies to phosphotyrosine.
The arrow indicates the Src*/Cas(SD) chimera. b) Cos-7 cells were transfected with vector alone (lane 1) or plasmid coding
for the Src*/Cas(SD) chimera (lane 2). The Src*/Cas(SD) chimera was then immunoprecipitated with antibodies to HA and
probed with anti-phosphotyrosine (top panel). The blot was then stripped and then probed with antibodies to HA to detect
the Src*/Cas(SD) chimera (bottom panel). The arrow indicates the Src*/Cas(SD) chimera.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/18
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Figure 4
v-crk specifically interacts with and enhances the tyrosine phosphorylation status of the 3' portion of the Cas SD chimera in
cells (SrcKM/Cas(SD)).a) Cos-7 cells were transfected with vector coding for the SrcKM/Cas(SD) chimera alone (lane 1), or
along with mutants of v-crk, WT (lane 2), SH2 mutant (lane 3) or SH3 mutant (lane 4). The SrcKM/Cas(SD) chimera was then
immunoprecipitated with antibodies to HA and probed with anti-phosphotyrosine (top panel). The blot was then stripped and
then probed with antibodies to HA to detect the SrcKM/Cas(SD) chimera (middle panel). The bottom panel shows the expres-
sion of the v-crk mutants in the transfection as determined by anti-gag blotting. Arrows point to the SrcKM/Cas(SD) chimera
and v-crk in the top, middle and bottom panels respectively. b) Cos-7 cells were transfected with the following plasmids, and
immunoprecipitated with anti-HA antibodies. SrcKM/Cas(5'SD) chimera (lane 1), SrcKM/Cas(3'SD) chimera (lane 2), and SrcKM/
Cas(SD) chimera (lane 3) alone, or along with WT v-crk (lanes 4–6). The top panel was probed with antibodies against phos-
photyrosine, and the bottom panel with antibodies against HA to detect the chimeras. Probing whole cell lysates with antibod-
ies to v-crk (anti-gag) demonstrated that cells leading to lanes 4–6 expressed equivalent levels of v-crk (data not shown).BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/18
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Figure 5
Tyrosine phosphorylated substrate domain of Cas blocks v-crk mediated transformation. a) NIH3T3 cells or those trans-
formed with v-crk were either transfected with vector alone or with vector carrying the Src*/Cas(SD) chimera. Whole cell
extracts (WCL) from cells were probed with anti-phosphotyrosine (top panel) or with anti-HA antibody (bottom panel). b)
NIH3T3 cells stably transfected with vector alone (left panel), with v-crk (middle panel) or v-crk and the Src*/Cas(SD) chimera
were assayed for growth in soft agar. Representative sections are shown. Colony numbers per view field were as follows: 26.1
(+/- 4.2) for v-crk alone vs. 2.9 (+/- 1.4), statistically significant (p = 7.76 ×  10-8, t-test).BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/18
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Figure 6
Tyrosine phosphorylated Cas substrate domain blocks activation of JNK. a) NIH3T3 cells stably transfected with vector alone,
the Src*/Cas(SD) chimera alone, v-crk alone or v-crk plus the Src*/Cas(SD) chimera were assayed for total cellular tyrosine
phosphorylation (top panel). JNK was immunoprecipitated and assayed for kinase activity against gst-c-jun in vitro (middle and
bottom panels). Lanes 1, 2 and 3, NIH3T3 vector transfected clones; lane 4 NIH3T3 transfected with the Src*/Cas(SD) chi-
mera; lanes 5 and 6, NIH3T3 transfected with v-crk; lane 7, NIH3T3/v-crk cells transfected with the Src*/Cas(SD) chimera.
Arrows are pointing to the Src*/Cas(SD) chimera (top panel), gst-c-jun (middle panel) and JNK (bottom panel). b) Cos-7 cells
were transiently transfected with gst-JNK alone, or along with v-crk, or v-crk plus the Src*/Cas(SD) chimera. gst-JNK was
immunoprecipitated and assayed for kinase activity against gst-c-jun in vitro (first panel). The expression levels of the gst-JNK,
v-crk and the Src*/Cas(SD) chimera were determined as indicated. Arrows are pointing to the gst-c-jun substrate (first panel),
gst-JNK (second panel), v-crk (third panel) and the Src*/Cas(SD) chimera (fourth panel).BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/18
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not transform NIH3T3 cells as no colonies of these cells
grew in soft agar (data not shown). Instead, expression of
tyrosine phosphorylated Cas SD chimera resulted in sig-
nificant reduction in the number of v-crk/NIH3T3 soft
agar colonies as well as their size (Fig. 5b), suggesting that
the Src*/Cas(SD) chimera blocked the ability of v-crk to
transform these cells.
Tyrosine phosphorylated Cas SD blocks JNK activation by 
v-crk
The JNK pathway is regulated by interaction of c- or v-crk
with Cas via the substrate domain [38]. In determining
which pathways are affected in our stable cell lines gener-
ated, we determined if JNK was activated in the v-crk
transformed cells, and if the tyrosine phosphorylated Cas
chimera was affecting this activation. JNK was immuno-
precipitated and tested for activity from control NIH3T3
cells, those expressing the Cas chimera and those express-
ing the Cas chimera and v-crk (Fig. 6a). We found that
while JNK activity was elevated in v-crk transformed
NIH3T3 cells, expression of the tyrosine phosphorylated
Cas chimera resulted in reduced activity of JNK (Fig. 6a, cf.
lanes 1, 5 and 7). Interestingly, JNK activity was also lower
in the NIH3T3 cells expressing the tyrosine phosphorylat-
ed Cas chimera than the vector transfected cells, suggest-
ing that this chimera also affected JNK activity in those
cells (Fig. 6a, cf. lanes 1 and 4). These data suggest that the
tyrosine phosphorylated Cas chimera perturbs signaling
via v-crk and probably via endogenous c-crk to affect the
activation of the JNK pathway.
We also verified that the tyrosine phosphorylated Cas chi-
mera could affect the ability of v-crk to activate the JNK
pathway in transient transfection experiments (Fig. 6b).
Transfection of v-crk along with gst-JNK into Cos-7 cells
resulted in activation of the co-transfected JNK (Fig. 6b, cf.
lanes 1 and 2). However, co-transfection of v-crk and gst-
JNK with the tyrosine phosphorylated Cas chimera
blocked the activation of JNK induced by v-crk (Fig. 6b, cf.
lanes 2 & 3), confirming that tyrosine phosphorylated Cas
SD can inhibit the ability of v-crk to activate the JNK path-
way. Transient expression of the Src* increased JNK activ-
ity slightly while expression of the SrcKM/Cas(SD) fusion
did not affect JNK activity (data not shown).
To determine if the tyrosine-phosphorylated Cas SD chi-
mera affected other signaling pathways, we tested whether
the association between c-crk and C3G was affected in
NIH3T3 cells expressing the chimera (Fig. 7a). Immuno-
precipitating endogenous c-crk and probing for associated
C3G demonstrated that C3G association with c-crk was re-
duced in the presence of the tyrosine phosphorylated chi-
mera (Fig. 7a, cf. lanes 3, 4 & 5). In addition, we
determined if tyrosine phosphorylation of endogenous
FAK and endogenous Cas was affected by the presence of
the chimera. This was not the case. Figure 7b demon-
strates that there was no difference in tyrosine phosphor-
ylation or association with tyrosine phosphorylated
proteins of either FAK or endogenous Cas upon stable ex-
pression of the tyrosine phosphorylated Cas SD chimera.
Tyrosine phosphorylated Cas SD acts as a decoy for v-crk 
and endogenous c-crk
As the tyrosine phosphorylated Cas substrate domain acts
as a dominant negative for v-crk mediated transformation
and JNK activation, and can also interact with v-crk and c-
crk (data not shown), we wanted to determine if it could
compete for binding of v- and c-crk to endogenous Cas.
We transfected v-crk alone or along with the chimera of
the attenuated Src kinase domain fused to the C-terminal
crk interacting region of the Cas substrate domain (Src*/
Cas(3'SD), carrying the YDXP motifs) into Cos-7 cells and
immunoprecipitated either the chimera or v-crk and as-
sayed for interacting tyrosine phosphorylated proteins
(Fig. 8a). Our analysis showed that expression of this chi-
mera resulted in expression of the highly tyrosine phos-
phorylated Cas 3'SD chimera (Fig. 8a, lanes 2 (whole cell
lysates) or lane 3, anti-chimera immunoprecipitate). Ex-
pression of v-crk alone resulted in its co-immunoprecipi-
tation with endogenous tyrosine phosphorylated Cas
(Fig. 8a, lane 4). By contrast, co-expression of v-crk with
the chimera resulted in reduction in the association of v-
crk with endogenous Cas and in induced association of v-
crk with the tyrosine phosphorylated Cas 3'SD (Fig. 8a,
lane 5). To determine if the tyrosine phosphorylated chi-
mera could compete with endogenous Cas for binding to
endogenous c-crk, we transfected either the isolated atten-
uated Src kinase domain as control, or the tyrosine phos-
phorylated Cas substrate domain (Src*/Cas(SD)) into
Cos-7 cells, and immunoprecipitated endogenous c-crk
(Fig. 8b).
Immunoprecipitation of endogenous c-crk showed asso-
ciation with endogenous Cas (Fig. 8b, lane 1), while co-
expression of the tyrosine phosphorylated Cas substrate
domain resulted in reduced association of endogenous c-
crk with endogenous Cas and association with the tyro-
sine phosphorylated chimera (Fig. 8b, lane 2). These data
suggest that the tyrosine phosphorylated substrate do-
main of Cas acts as a decoy for binding to v- and c-crk
thereby interfering with signaling to JNK activation and
transformation.
Discussion
Adaptor proteins that regulate tyrosine kinase signaling
pathways fall into two major categories, those primarily
with protein/protein interaction domains such as SH2,
SH3, PTB, and PH domains, exemplified by the adaptor
proteins c-crk, nck and grb-2, and those that are primarily
tyrosine phosphorylated, exemplified by proteins such asBMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/18
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Figure 7
Tyrosine phosphorylated Cas substrate domain affects c-crk interaction with C3G, but not endogenous FAK or Cas tyrosine
phosphorylation.a) Lysates from NIH3T3 cells stably carrying vector alone or expressing the Src*/Cas(SD) chimera were
immunoprecipitated with anti-phosphotyrosine (top panel), or anti-crk (middle and bottom panels) and probed with anti-HA
to detect the Src*/Cas(SD) chimera (top and middle panels), or C3G (bottom panel). Lanes 1 and 2, vector and the Src*/
Cas(SD) chimera transfected NIH3T3 cells respectively, whole cell extract; lanes 3 and 4, vector transfected NIH3T3 cells
immunoprecipitated with anti-phosphotyrosine antibody; lane 5, NIH3T3 cells expressing the Src*/Cas(SD) chimera immuno-
precipitated with anti-phosphotyrosine antibody. Arrows indicate the Src*/Cas(SD) chimera and C3G in the top, middle and
bottom panels. b) A duplicate blot to that shown in (a) was probed with anti-Fak antibodies (top panel) or with anti-Cas anti-
bodies (bottom panel). Arrows indicate FAK and Cas.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/18
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Figure 8
The tyrosine phosphorylated Cas substrate domain competes with endogenous Cas for binding to v- and c-crk. a) Cos-7 cells
were transfected with vector alone (lane 1), the Src*/Cas(3'SD) chimera alone (lanes 2 and 3), v-crk alone (lane 4) or the Src*/
Cas(3'SD) chimera along with v-crk (lane 5). The Src*/Cas(3'SD) chimera or v-crk was then immunoprecipitated and probed
for phosphotyrosine. Note that v-crk normally associates with more Cas when transfected alone compared when transfected
with the Src*/Cas(3'SD) chimera. b) Cos-7 cells were transfected with vector (lane 1) or the Src*/Cas(SD) chimera (lane 2).
Endogenous c-crk was then immunoprecipitated and probed with anti-phosphotyrosine (top panel) or with anti-c-crk (bottom
panel).BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/18
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Cas, Dok, IRS-1 and 2, Slp-76, LAT, TRIM or SIT. The latter
class may also have protein/protein interaction domains.
The former class of adaptor proteins form complexes with
downstream effectors in a constitutive fashion via their
SH3 domains. Signals are initiated by tyrosine phosphor-
ylation of upstream effectors that recruit these adaptors to
assemble larger protein complexes by bringing down-
stream effectors to the distinct cellular compartments for
activation. Thus c-crk interacts constitutively with down-
stream effectors such as C3G via its SH3 domains, and in-
teracts in a phosphotyrosine dependent fashion with
tyrosine phosphorylated receptors using its SH2 domain
[39]. To analyze downstream signals regulated by these
adaptor proteins, investigators have developed methods
that target them to distinct cellular membrane compart-
ments by using heterologous targeting sequences. This
leads to the generation of constitutive signals by the adap-
tor proteins in the absence of other upstream signals [40].
The second class of phosphotyrosine dependent adaptors
exemplified by proteins such as Cas, Dok, IRS-1 and 2 or
Slp-76, as cytosolic adaptors, or LAT, TRIM or SIT as mem-
brane anchored adaptors, also require the activation of
upstream signals by tyrosine kinases for their function.
This second class of adaptor proteins is characterized by a
substrate domain with multiple tyrosines for phosphor-
ylation by upstream kinases. Phosphorylation of these
sites leads to recruitment of other proteins, including the
first class of adaptor proteins with SH2 or PTB domains,
and subsequent signal transmission (see [41] for review).
Analysis of the specific signals emanating from the second
class of adaptor proteins has been difficult due to their de-
pendence on upstream kinases for tyrosine phosphoryla-
tion of the substrate domains for subsequent assembly of
downstream effectors. While these upstream kinases lead
to tyrosine phosphorylation of the adaptor and activation
of downstream effectors, they usually also activate other
signaling pathways that can confound analysis of the spe-
cific role of the tyrosine phosphorylated adaptor protein.
We describe a novel chimeric molecule approach that al-
lows the analysis of signaling events regulated by adaptor
proteins that require tyrosine phosphorylation by up-
stream signals for which we used the Cas protein as a
model. The adaptor protein Cas has several domains that
are important for its function, an SH3 domain, a central
substrate domain with up to 15 tyrosines that can serve as
tyrosine kinase substrates for upstream kinases such as Src
and Abl [19,42,43], and a C-terminal Src binding domain
with PXXP motifs for binding to the SH3 domain of Src,
and two tyrosines providing docking sites for the Src SH2
domain upon phosphorylation [6]. The substrate domain
of Cas has two major types of tyrosine motifs that can be
phosphorylated and bind downstream effectors, YQXP (4
copies) and YDXP motifs (9 copies), suggesting that at
least two classes of downstream effectors, one capable of
binding to YDXP motifs and the other capable of binding
to YQXP motifs, are assembled by this adaptor protein.
Tyrosine phosphorylation of the substrate domain leads
to the recruitment of other downstream adaptors such as
crk and nck, as well as other downstream effectors pos-
sessing SH2 domains, and signaling events attributed to
this domain include activation of the JNK MAPK pathway
and control of adhesion and migration of cells
[6,10,16,38,44]. We constructed a chimera between a ki-
nase that phosphorylates Cas in vivo and the substrate do-
main of Cas, in order to determine events regulated by
this domain. We constructed chimeras by placing the Cas
SD at either the N-terminus or C-terminus of the Src ki-
nase domain. However, we found that placing the Cas SD
at the N-terminus of the Src kinase domain was inferior to
placing it at the C-terminus with regards to tyrosine phos-
phorylation of the Cas SD. Subsequently, in all our exper-
iments reported, we used chimeras of the Cas SD fused to
the C-terminus of the Src kinase domains. Rather than the
WT kinase domain of Src, we used an attenuated Src ki-
nase domain (Y416F) as the fusion partner for our chime-
ra to avoid phosphorylation and activation of other Src
substrates that would occur with a WT kinase domain (da-
ta not shown, [35]). The attenuated Src kinase domain has
reduced kinase activity and does not phosphorylate exog-
enous substrates [35]. We also used a kinase inactive Src
kinase domain as a control fusion protein. The chimera of
the Cas SD domain fused to the attenuated Src kinase do-
main was highly tyrosine phosphorylated in cells, and
could bind known Cas binding proteins in cells. In con-
trast, the chimera containing the kinase inactive domain
was not stably phosphorylated in cells. These findings in-
dicated that this approach would be useful in analyzing
the events that occur following tyrosine phosphorylation
of the Cas SD in the absence of upstream signals that may
activate other signaling pathways. Our initial experiments
were designed to determine whether tyrosine phosphor-
ylation of the SD of Cas would lead to the assembly of
protein complexes and activation of downstream effec-
tors.
Using different regions of the Cas SD containing either the
YDXP or the YQXP motifs, we could demonstrate that v-
crk specifically interacts with the C-terminal YDXP motifs
when tyrosine phosphorylated. Moreover, in the absence
of stable tyrosine phosphorylation as seen in the Src ki-
nase inactive fusions, v-crk could either induce their phos-
phorylation, or protect transiently phosphorylated YDXP
motifs from dephosphorylation through yet unknown
mechanisms. Thus while both sets of motifs in the Cas SD
have been thought to interact with the v-crk SH2 domain,
we demonstrated that this domain only interacts with the
YDXP motifs. Since crk is the major protein reported to
bind to the Cas SD, our data suggest that the YQXP motifsBMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/18
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may interact with other yet to be identified downstream
effectors.
We also found that while downstream effectors assemble
onto the tyrosine phosphorylated Cas SD domain, the
downstream signals were not activated. In particular, we
found that the tyrosine phosphorylated Cas SD domain
blocked v-crk mediated activation of the JNK pathway. In
addition, we found that expression of the tyrosine phos-
phorylated Cas SD domain in v-crk transformed cells re-
duced their ability to grow in soft agar, a measure of their
transformation. Furthermore, we found that the tyrosine
phosphorylated Cas SD competed effectively with the en-
dogenous Cas for binding to v-crk and endogenous c-crk,
while not affecting tyrosine phosphorylation of proposed
upstream proteins such as Fak and endogenous Cas. Thus,
our data suggest that the tyrosine phosphorylated Cas SD
acts as a decoy for endogenous Cas binding proteins and
blocks signaling via crk to the activation of JNK, as well as
transformation of cells by the oncogene v-crk. The ability
of the tyrosine phosphorylated Cas SD to act as a decoy
suggests that while tyrosine phosphorylation of the sub-
strate domain of Cas may be important for its function in
assembling downstream signals, specific localization of
Cas may also be critical for its downstream functions. In-
deed, phosphorylated endogenous Cas is localized to FAK
and the focal adhesions via its SH3 domain and/or its Src
binding domain in its distal C-terminus, both were ex-
cluded from our chimera, suggesting that proper localiza-
tion of the tyrosine phosphorylated substrate domain
may be required for Cas activity [30,45].
Conclusions
A number of proteins have been identified that bind to
the substrate domain of Cas, however the large number of
tyrosines and potential binding sites for downstream ef-
fectors suggest that there may be more. We propose that
our chimeric approach can be used to identify Cas bind-
ing proteins in mammalian cells in the absence of specific
upstream signals normally required for tyrosine phospho-
rylation of the Cas substrate domain. We can also use this
approach to ask which tyrosines within the SD of Cas can
act as decoys for specific downstream signals attributed to
the SD of Cas. Other uses for such a chimera include
screening approaches such as the yeast two-hybrid screen
to select proteins that interact with the tyrosine phospho-
rylated Cas SD. Finally, we can theoretically target this ty-
rosine phosphorylated chimera to specific areas of the cell
to determine which cellular localization will recover the
activation of downstream Cas functions. This chimeric ap-
proach can also be extended to other adaptor proteins that
require upstream signals for tyrosine phosphorylation,
creating tyrosine phosphorylated decoys or targeting tyro-
sine phosphorylated substrate domains or full length
adaptor proteins in transgenic cellular and animal sys-
tems. We also propose that similar approaches could be
used for analyzing proteins that are phosphorylated on
serine or threonine and assemble complexes, such as 14-
3-3, for analysis of their downstream signals or identifica-
tion of binding proteins.
Materials and Methods
Materials
Antibodies against the following proteins were obtained
from the following suppliers or individuals: ant-phospho-
tyrosine, RC20-HRP (Transduction Laboratories, Lexing-
ton, KY); anti-HA (Boehringer Mannheim, Indianapolis,
IN); anti-gag (Dr. R. Birge, New Jersey Medical School, Ne-
wark, NJ); anti-JNK (NEB, Beverley, MA); anti-c-crk (Santa
Cruz Biotechnology, Santa Cruz, CA); anti-C3G (Dr. Bea-
trice Knudsen, Weill Medical College of Cornell Universi-
ty, NY, NY); anti-FAK and anti-Cas (Transduction
Laboratories, Lexington, KY).
Cloning and chimera construction
The kinase domains of the c-Src Y416F mutant (kind gift
of Dr. Joan Brugge, Harvard Medical School, Boston, MA)
or the kinase inactive c-Src (K295M, [46]), were amplified
by PCR and cloned in pJ3H and pJ3M, two vectors for HA-
and Myc-tagging at the N-terminus of the protein (kind
gifts from Dr. J. Chernoff, Fox Chase Cancer Center, Phil-
adelphia, PA, [47]). The pEBG-JNK was a kind gift of Dr.
Bruce Mayer (Harvard Medical School, Boston, MA). The
substrate domain of Cas (Fig. 1, a.a. L157 to R516) was am-
plified by PCR and fused in frame to the C-terminus of the
attenuated SrcY416F kinase domain (Src*), or to the C-
terminus of the inactive SrcK295M kinase domain
(SrcKM). Subfragments of the Cas substrate domain were
generated in the same fashion, with the N-terminal sub-
domain (a.a. L157 to A324, 1 YKVP motif and 4 YQXP mo-
tifs) and the C-terminal subdomain (a.a. S325 to R516, 9
YDXP motifs) of Cas amplified. Experiments used the chi-
meras expressed either via the pJ3H vector, or the HA-
tagged chimera subcloned into the expression vector
pMEXneo [48]. The oncogene v-crk and its mutants
cloned into pMEXneo have been described [49,50].
Cell culture and transfection and soft agar assays
Cos-7 and NIH3T3 cells were grown in DMEM containing
10% FCS and antibiotics at 37°C with 5% CO2. Cos-7
cells were transfected by calcium phosphate method,
while the NIH3T3 cells were transfected using Lipofectin
(Gibco, BRL). Growth of cells in soft agar was performed
as described [51].
Cell Lysis, Immunoprecipitation and Kinase Assays
Cell lysis, Immunoprecipitation, SDS-PAGE, and Western
blotting were performed exactly as described [48]. Tyro-
sine phosphorylation of chimeras and other substrates
were determined following immunoprecipitation usingBMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/18
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the indicated antibodies and probing with RC20-HRP
anti-phosphotyrosine antibodies. Expression of the chi-
meras was determined with anti-HA antibodies. Western
blots were developed using ECL+ (Amersham Pharma-
cia).
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